Vishal Manchanda
Long/short equity, Deep Value, special situations, contrarian

Sell Ranbaxy - Recent Run Up Provides An Opportunity For Investors To Exit

The stock price of Ranbaxy (OTC:RBXLY), subsidiary of Japan based Daiichi Sankyo (OTCPK:DSKYF) is up 30 percent over the last 3 months (as against 13.1% by other specialty generic companies) and I believe this is an opportune time for investors to cash in. The run up is in expectation of a turnaround driven by a few first to file (NYSEMKT:FTF) generic drug launches (Nexium and Valcyte generics) and upside from a strong ramp up of its acne drug Absorica (Isotretinoin) in the US. I believe there is over optimism surrounding the stock and it makes sense to exit,

· There is a strong chance that Ranbaxy may not be able to capitalize on these...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details